Claims cover methods of treating pancreatic cancer in combination with Stereotactic Ablative Radiotherapy (SABR)
Additional U.S. patent further bolsters strong IP protection around IMM-101
Uxbridge, UK – 31st May 2022 – Immodulon, the immuno-oncology company, today announced that the U.S. Patent and Trademark Office issued US Patent No. 11,318,193 on May 3, 2022, relating to IMM-101, the Company’s investigational treatment comprising heat-killed Mycobacterium obuense, for the treatment of pancreatic cancer.
The granted claims cover methods of treatment of primary or metastatic pancreatic cancers with IMM-101 in combination with fractionated regimens of targeted radiotherapies, which include the likes of Stereotactic Ablative Radiotherapy (SABR). This particular combination is currently being explored under Investigator-initiated studies at the Erasmus University Medical Center Rotterdam. These phase I/II LAPC-2 and MEPANC-1 clinical trials, led by Professor Casper van Eijck, are investigating IMM-101 and SABR in locally advanced pancreatic cancer and oligo-metastatic pancreatic cancer, respectively.
This patent issuance follows the granting of six other U.S. patents with claims directed to specific combinations with checkpoint inhibitors (CPIs) in the treatment of various cancers, including sarcoma, melanoma, colorectal cancer, pancreatic cancer, and others. Immodulon’s patent portfolio includes granted claims covering treatment of certain cancers using a combination of IMM-101 with classes of CPIs with members having regulatory approval in other treatments, including CPIs targeting cytotoxic T lymphocyte antigen 4 (CTLA-4), programmed cell death protein 1 (PD-1), and programmed cell death ligand 1 (PD-L1). This latest issuance also helps further realise Immodulon’s vision for IMM-101 to be combined with standard-of care treatments under the four major pillars of cancer therapy – immunotherapy, chemotherapy, radio/ablation therapy and surgery. Immodulon intends to conduct further clinical studies related to the granted claim scope as well as advance IMM-101 into other cancers with high unmet need. This newly granted US patent is expected to expire in February 2032.
Cellia K. Habita, M.D., PhD, Chief Executive Officer of Immodulon, commented:
“We are pleased to have received this granted US patent which significantly broadens our patent protection for IMM-101. These granted claims cover treatment of pancreatic cancers with IMM-101 and radiotherapy, a promising combination which we are currently investigating in ongoing clinical trials. We continue to pursue strong, broad intellectual property protection for IMM-101, with a growing patent estate covering the treatment of specific cancers with high unmet medical need. The issuance of this U.S. patent will support ongoing discussions with third parties.”
About Immodulon Therapeutics
Immodulon Therapeutics Ltd. (London, UK) is a privately-owned, clinical-stage, immuno-oncology company primarily focused on the development of safe, effective and novel treatments for cancer. Its lead drug candidate, IMM-101, has shown promise in early clinical trials, demonstrating potential for the platform. It contains heat-killed whole cell Mycobacterium obuense which activates dendritic cells and other cells of the innate immune system predominantly via Toll-like receptor 2. It is Immodulon’s vision that IMM-101 will become a backbone immunotherapy across multiple tumour types. Its unique mechanism of action should not only make this product applicable to a range of cancers but, in combination with immune checkpoint inhibitors and any other standard-of-care treatment of the four major pillars of cancer therapy – immunotherapy, chemotherapy, radio/ablation therapy and surgery – it is also expected to increase their efficacy without compromising patient safety or quality of life. For more information about Immodulon, please visit www.immodulon.com.